CPB2208

CPB2208 is an investigational antiviral drug candidate developed by Corepharmbio, a South Korean pharmaceutical company specializing in advanced drug delivery systems. The drug is being developed using Corepharmbio's proprietary **OD!FS** (Oral Dissolving in a Few Seconds) platform technology, which creates orally disintegrating formulations, such as powders or films, that dissolve rapidly in the mouth without the need for water. This technology is designed to improve patient compliance and ease of administration, particularly for pediatric and geriatric patients or those with dysphagia (difficulty swallowing). CPB2208 is currently in the early stages of development for the treatment of viral infections.